Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients

Abstract

BACKGROUND: Chronic hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. OBJECTIVE: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/daclatasvir versus sofosbuvir/ledipasvir for treatment of non‐cirrhotic naïve patients for 12 weeks in CHC patients. SETTING: The current study was conducted in Hepatology clinic at Beni‐Suef general hospital. METHOD: One hundred patients (70 females, 30 males) were recruited from Hepatology clinic at Beni‐Suef general hospital. Patients were randomly allocated into two groups that received a 12 weeks treatment of either sofosbuvir 400 mg/daclatasvir 60 mg or sofosbuvir 400 mg/ledipasvir 90 mg. The sustained virological response 12 weeks post treatment (SVR12) (HCV RNA